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Kidney Injury Molecule-1 (KIM-1): A novel biomarker for Acute renal failure (ARF) is an important cause of
human renal proximal tubule injury. morbidity and mortality in hospitalized patients. The mor-
Background. Traditional blood and urine markers for the tality rate of patients with severe ARF requiring dialysisdiagnosis of various renal diseases are insensitive and non-
has not decreased significantly over the last 50 yearsspecific. Kidney Injury Molecule-1 (KIM-1) is a type 1 trans-
despite advances in supportive care [1]. Mortality of pa-membrane protein, with an immunoglobulin and mucin domain,
whose expression is markedly up-regulated in the proximal tu- tients with postoperative renal failure ranges from 24 to
bule in the post-ischemic rat kidney. The ectodomain of KIM-1 100%, and 50 to 70% among patients in intensive care
is shed from cells. The current studies were carried out to evalu- units who require dialysis [2–5]. Mortality is directly pro-ate whether KIM-1 is present in human acute renal failure and
portional to the magnitude of rise in serum creatininemight serve as a urinary marker of acute renal tubular injury.
[3, 6, 7]. It has been postulated that introduction of ther-Methods. Kidney tissue samples from six patients with bi-
opsy-proven acute tubular necrosis (ATN) were evaluated by apy early in the disease process will reduce the mortality
immunohistochemistry for expression of KIM-1. Urine samples rate associated with ARF. The identification of reliable
were collected from an additional thirty-two patients with vari-
biomarkers for tubule injury would be useful to facilitateous acute and chronic renal diseases, as well as from eight
early intervention, evaluate the effectiveness of thera-normal controls. Urinary KIM-1 protein was detected by immu-
noassay and was quantified by ELISA. peutic interventions, and guide pharmaceutical develop-
Results. There was extensive expression of KIM-1 in proxi- ment by providing an indicator for nephrotoxicity.
mal tubule cells in biopsies from 6 of 6 patients with confirmed The most frequently used serologic indicators for the
ATN. The normalized urinary KIM-1 levels were significantly
diagnosis of renal disease are serum creatinine, serumhigher in patients with ischemic ATN (2.92  0.61; N  7)
urea nitrogen, and creatinine clearance, all of which arecompared to levels in patients with other forms of acute renal
failure (0.63  0.17, P  0.01; N  16) or chronic renal disease insensitive and nonspecific for detection of renal injury
(0.72 0.37, P 0.01; N 9). Adjusted for age, gender, length [8]. Many urinary proteins and biochemical markers have
of time delay between the initial insult and sampling of the been evaluated as noninvasive indicators of renal injuryurine, a one-unit increase in normalized KIM-1 was associated
[9–14]. However, attempts to use them as general mark-with a greater than 12-fold (OR 12.4, 95% CI 1.2 to 119)
ers to screen patients for renal injury and to identify therisk for the presence of ATN. Concentrations of other urinary
biomarkers, including total protein, -glutamyltransferase, and site of injury within the kidney have been disappointing.
alkaline phosphatase, did not correlate with clinical diagnostic The proximal tubule is particularly sensitive to isch-
groupings. emic injury in animal models [15]. Surviving cells in thisConclusions. A soluble form of human KIM-1 can be de-
segment undergo an active process of dedifferentiationtected in the urine of patients with ATN and may serve as a
useful biomarker for renal proximal tubule injury facilitating and proliferation after ischemia ultimately resulting in
the early diagnosis of the disease and serving as a diagnostic the reconstitution of a well differentiated polarized mor-
discriminator. phology [16–18]. We have cloned a novel molecule, Kid-
ney Injury Molecule-1 (KIM-1), from rats, mice and hu-
mans. KIM-1 is markedly up-regulated in postischemic
rat kidney [19]. The KIM-1 ectodomain is shed into theKey words: acute renal failure, acute tubular necrosis, contrast ne-
phropathy, urinary biomarker, ischemia, dialysis, nephrotoxicity. extracellular milieu of human 769-P (human kidney ade-
nocarcinoma cells) and HK-2 (human kidney proximalReceived for publication August 18, 2001
tubular cells) cell lines which express KIM-1 under nor-and in revised form February 25, 2002
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kidney biopsy sections were examined for expression of and serum urea nitrogen concentrations were obtained
from review of patients’ records.the KIM-1 protein and urine samples were collected
from other patients with various acute and chronic renal
Immunohistochemistrydiseases. Urinary KIM-1 protein levels were compared
Human kidney biopsy sections from six kidneys werewith levels of urinary -glutamyltransferase (GT), alka-
deparaffinized, and endogenous peroxidase activity wasline phosphatase, and total protein as potential biomark-
ablated by incubation in 2% hydrogen peroxide in meth-ers for tubule injury in various renal diseases.
anol for 20 minutes. The sections were heated with a
microwave oven in 0.1 mol/L citrate buffer, pH 6.0 for
METHODS 10 minutes, and were blocked with 1.5% horse serum in
Renal biopsy samples PBS at room temperature for one hour. AKG7 anti-
human KIM-1 monoclonal antibody was then added toHuman kidney biopsy sections from six patients with
the sections and incubated overnight at 4C with 50 La confirmed pathological diagnosis of acute tubular ne-
of antibody at 5 g/mL in blocking solution. After appli-crosis (ATN) were randomly obtained and evaluated for
cation of the primary antibody, KIM-1 was detectedexpression of the KIM-1 protein by immunohistochemis-
using a commercially available Vectastain Elite ABCtry. All these biopsy sections were collected previously
kit (for mouse IgG) with DAB Substrate (Vector Labs,for other medical indications. Urine samples from these
Burlingame, CA, USA) kit for peroxidase staining. Thepatients were not available.
sections were counterstained with hematoxylin.
Patient selection for urine collections
Urine samples
Forty patients were studied for the presence of KIM-1
Collected fresh urine samples were centrifuged to re-protein in the urine: 23 with ARF; 9 with chronic renal
move cellular components. Protease inhibitor cocktail tab-diseases (CRD); and 8 normal individuals with no evi-
lets (Boehringer Mannheim, Mannheim, Germany) weredence of renal disease. The 23 patients with various causes
added to the transferred supernatant. Urine analysis in-of ARF were randomly selected from patients seen for
cluded urinary dipstick (Multistix 8 SG; Bayer Corpora-renal consultation at Massachusetts General Hospital
tion, Tarrytown, NY, USA) and microscopic examina-
from June 1998 to February 2000 (8 females, 15 males;
tions of sediment (Olympus microscope), which were
aged 17 to 85 years, mean 61 years old). An individual
performed prior to storage at 80C.
was considered to have ARF if the patient’s serum creati-
nine value either (1) increased by at least 0.5 mg/dL Monoclonal antibodies against human KIM-1
when the baseline serum creatinine level was less than Highly specific murine monoclonal antibodies were
2.0 mg/dL; (2) increased by at least 1.5 mg/dL when the raised against the extracellular domain of human KIM-1
baseline serum creatinine value was greater than or equal and were purified from ascites fluid or hybridoma con-
to 2.0 mg/dL; or (3) increased by at least 0.5 mg/dL, re- ditioned medium (a more complete description of these
gardless of the baseline serum creatinine, as a conse- antibiotics is submitted for publication by Bailly V et al).
quence of exposure to radiographic agents. The urine sedi- Monoclonal antibodies designated ARD5, ACA12 and
ment was classified as abnormal if muddy-brown casts, AKG7 were used for this study. ARD5, which recognizes
coarse granular casts, multiple fine granular casts, white the native protein and binds to the Ig-like domain, was
cell casts, red cell casts or renal tubular cells were pres- used as a trapping antibody in the immunoextraction
ent. Nine patients with various CRD were randomly and the enzyme-linked immunosorbent assay (ELISA),
selected from the renal clinic at Massachusetts General while AKG7 and ACA12 were used as detection anti-
Hospital during the same interval (7 females, 2 males; bodies for Western blots and ELISA read out. AKG7
aged 30 to 74 years, mean 54 years old). Patients included antibody was labeled with biotin using the sulfo-NHS-
in this group (1) had an established renal disease which biotin (Pierce Chemical Co., Rockford, IL, USA) and
was diagnosed by renal biopsy and/or by serological was used as detection antibody for immunohistochem-
study; and (2) had a relatively stable (0.5 mg/dL) serum istry.
creatinine level for at least six months. Chronic renal
Immunoextraction, Western blot analysis, anddiseases represented in this study include Wegener’s
ELISA immunoassaygranulomatosis, focal segmental glomerulosclerosis, sys-
temic lupus erythematosus (SLE) nephropathy, diabetic Urinary soluble KIM-1 protein was detected by immu-
nephropathy and chronic renal allograft dysfunction. noextraction followed by Western blot analysis and was
Urine samples were also collected from 8 individuals quantified by ELISA. Briefly, the wells of an ELISA plate
with no known renal disease. Gender, diagnoses, comor- (MaxiSorp; Nunc, Naperville, IL, USA) were coated with
ARD5 anti-human KIM-1 monoclonal antibody [over-bid conditions, time of onset of ARF, serum creatinine,
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Table 1. Expression of KIM-1 in human kidney biopsy sections with acute tubular necrosis
KIM-1 expression KIM-1 expression
Cause of acute tubular necrosis in proximal tubules in glomeruli
Ischemia with minimal change disease Yes No
Early allograft dysfunction without rejection Yes No
Ischemia with allergic interstitial nephritis Yes No
Ischemia in setting of NSAID use and membraneous nephropathy Yes No
Early allograft dysfunction without rejection Yes No
Ischemia with vasculitis Yes No
NSAID is nonsteroidal anti-inflammatory drug.
night incubation at 4C with 300 L of antibody at 25 tests. Logistic regression was used for multivariate analy-
g/mL in phosphate buffered saline (PBS)]. The wells sis, and all P values are two tailed. Statistical analysis
were blocked with a bovine serum albumin (BSA) solu- was performed using SAS (SAS Institute, Cary, NC,
tion (1% in PBS) and were washed four times with PBST USA). Data are expressed as means  SE.
(PBS with 0.05% Tween 20). For immunoextraction fol-
lowed by Western blot analysis, the wells were incubated
RESULTSwith 250L urine samples at room temperature for three
hours. After four washes with PBST, samples were mixed Expression of KIM-1 in the proximal tubules with
with 25 L Laemli loading buffer containing 5% -mer- acute tubular necrosis.
captoethanol, heated five minutes at 95C. Twenty mi- The expression of KIM-1 was evaluated in six ran-
croliters were loaded on a 4 to 20% polyacrylamide gel. domly selected biopsies in which a pathological diagnosis
After electrophoresis, the proteins were electrotransf- of ATN had been assigned. The underlining cause of ATN
erred onto a nitrocellulose sheet. The blot was blocked
in these patients is presented in Table 1. KIM-1 is ex-with a 5% nonfat dry milk solution in PBST and probed
pressed on the apical aspect of proximal tubule epithelialwith hybridoma supernatant (ACA12 or AKG 7) in
cells in all six patients. A typical staining pattern is dem-the blocking solution, followed by horseradish peroxide
onstrated in Figure 1. KIM-1 was not present in glomer-(HRP)-conjugated goat anti-mouse IgG antibodies di-
uli. KIM-1 was not detectable in normal kidney tissueluted in the blocking solution. The reactive bands were
derived from a patient with renal cell carcinoma (Fig.revealed by electrochemiluminescence. For ELISA, the
1). Urine was not available from these patients.wells were incubated with 100 L urine samples at room
temperature for three hours. After four washes with
Characteristics of patients from whom urine wasPBST, biotinylated AKG7 antibody was added, followed
examined for the presence of KIM-1by HRP-conjugated streptavidin. The urinary KIM-1 con-
Clinical characteristics of all patients from whom urinetent was expressed in absolute terms and also normalized
to the urinary creatinine concentration. was evaluated for the presence of KIM-1 are reported
in Table 2. Patients with ischemic ATN (N  7) were
Analytical tests diagnosed based on evidence for tubular cell injury in-
Urinary total protein, creatinine, alkaline phosphatase, cluding muddy-brown or granular casts in urine sedi-
and -glutamyltransferase (GT) were measured by Ani- ments, clinical history, and elevation of serum creatinine
Lytics Inc. (Gaithersburg, MD, USA) with a Hitachi 717 and blood urea nitrogen. Table 3 summarizes the causes
Analyzer. Total protein was measured with Pyrogallol- of ischemic ATN, the baseline and peak level to which
Red reagent (Biotrol Diagnostic, Chennevie`ie´-res les- serum creatinine increased, the serum creatinine at the
Louvres, France). Different system Packs (Boehringer time of urine collection, the day of urine collection and
Mannheim Diagnostics) were used to measure the creati- the day that the serum creatinine reached its peak. Ische-
nine (Jaffe System Pack), alkaline phosphatase (Amino-
mia, either to the native kidney (6/7), or a renal cadavericmethyl-propanol System Pack) and GT (Glycyl-glycone
allograft (1/7) was the cause of ATN in each of the sevenSystem Pack). These values were normalized to the uri-
patients. In four patients the ischemia was associatednary creatinine concentration. Serum creatinine was
with sepsis and in two other patients a cardiac arrest andmeasured by the Jaffe´ creatinine assay using a Roche/
cardiogenic shock accompanied a myocardium infarc-Hitachi 917 system. (Roche Diagnostics, Indianapolis,
tion. One patient had delayed allograft function afterIN, USA).
cadaveric renal transplant. In six of seven patients urine
Statistical analysis was collected prior to the day when serum creatinine
reached its peak. In the seventh patient urine was col-Categorical variables were analyzed using chi square
tests, and continuous variables using Mann Whitney-U lected on the same day that serum creatinine reached
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Fig. 1. KIM-1 expression in a normal human kidney (A) and one with acute tubular necrosis; (B) human kidney paraffin sections are stained for
KIM-1 using the AKG7 anti-human KIM-1 monoclonal antibody, and an ABC peroxidase detection system with DAB substrate (Vector). Normal
kidney tissue was taken from a patient with renal cell carcinoma.
Table 2. Baseline characteristics of patients with renal diseases and control
Ischemic ATN Contrast nephropathy Other ARF CRD Normal
Characteristic (N  7) (N  7) (N  9) (N  9) (N  8)
Age years 63.04.7 69.32.6 52.38.3 53.65.5 38.91.3
Sex M/F 4/3 4/3 7/2 2/7 4/4
Baseline serum creatinine mg/dL 1.60.6 1.90.1 1.80.2 2.60.6
Peak serum creatinine mg/dL 4.90.9 4.50.8 4.60.9
Serum creatinine at time of urine
collection mg/dL 3.80.7 3.80.8 3.80.8 2.60.6
Abbreviations are: ATN, acute tubular necrosis; other ARF, acute renal failure not associated with ischemia and contrast nephropathy; CRD, chronic renal
diseases. Values are means  SE.
Table 3. Summary of patients with Ischemic ATN
Baseline Peak
SCr at time of urine KIM-1 Normalized Time to reach Time of urine
Patient Sex Age Etiology SCr mg/dL collection mg/dL ng/mL KIM-1 peak SCr days collection day
1 M 75 Ischemia: cardiogenic shock 1.3 3.4 3.4 2.95 5.01 18 18
2 F 56 Ischemia: delayed graft function 5.1 8.7 7.0 2.99 2.46 5 2
3 M 51 Ischemia: sepsis 0.7 1.9 1.2 1.34 1.90 6 3
4 M 63 Ischemia: sepsis 1.0 5.5 4.3 1.81 1.28 12 11
5a F 47 Ischemia: sepsis 0.9 4.3 2.1 1.50 5.30 7 4
6 F 68 Ischemia: sepsis 1.2 7.6 5.3 2.00 2.80 11 3
7 M 81 Ischemia: cardiac arrest 2.2 3.1 2.3 1.40 1.70 5 1
Abbreviations are: M, male; F, female; SCr, serum creatinine.
a Patient required dialytic support
its peak level. One patient (# 5) required dialytic support. blood urea nitrogen temporally related to the contrast
dye exposure; and (3) rapidly reversible ARF. PatientsIn patients with contrast nephropathy (7/7 patients),
urine granular casts and/or renal tubular cells were pres- with other forms of ARF (9/9 patients) had no urine
casts. This group included five patients with pre-renalent. One patient whose contrast ARF was complicated
by rhabdomyolysis had muddy brown casts. Each of azotemia, two with late allograft rejection in the setting
of chronic cyclosporine administration, one with postob-these patients with contrast-induced ARF had (1) at
baseline, chronic renal insufficiency prior to the exposure structive nephropathy, and one with acute interstitial
nephritis. Patients with acute interstitial nephritis (N to contrast media; (2) exposure to contrast dye with a
well documented elevation of serum creatinine and 1), or late allograft rejection (N  2) were diagnosed by
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Table 4. Comparison of KIM-1 concentration and KIM-1 levels
normalized to urine creatinine concentration
for various forms of renal diseases
KIM-1 Normalized
ng/mL KIM-1
Ischemic ATN 2.000.26 2.920.61
Contrast nephropathy 0.340.13a 0.850.30a
Other ARF 0.130.02a 0.480.19a
Contrast nephropathy & other ARF 0.220.06a 0.640.17a
Fig. 2. Western blot analysis of urine collected from patients with CRD 0.690.41b 0.720.37a
different forms of renal failure. Each lane represents protein immunoex-
Abbreviations are: ATN, acute tubular necrosis: other ARF, acute renal failuretracted from urines of patients without renal disease, with ischemic
not associated with ischemia and contrast nephropathy; CRD, chronic renalATN, other forms of ARF (prerenal azotemia, contrast nephropathy,
diseases. Values are means  SE.post-renal), or chronic diseases (systemic lupus erythematosus nephrop- a P  0.01, bP  0.02, vs. ATN-ARFathy, SLE; diabetic nephropathy, DM). After immunoextraction and
PAGE, Western blot analysis was carried out with the AKG7 anti-
KIM-1 antibody.
renal biopsies. A patient with postobstructive nephropa-
thy (N  1) was diagnosed by renal ultrasound, which
disclosed the presence of bilateral hydronephrosis due
to obstruction of the ureters by prostate carcinoma. Pa-
tients with prerenal azotemia (N  5) were assigned this
diagnosis after intrarenal and postrenal etiologies were
excluded; benign urine sediments were documented and
renal function returned to baseline levels with improved
renal perfusion.
Detection of a soluble released form of human urinary
KIM-1 protein
Western blot results, presented in Figure 2, reveal low
levels of urinary KIM-1 in samples from patients without
acute or chronic renal disease. Although urine samples
Fig. 3. Comparison of urinary KIM-1 concentration in various formsfrom patients with either (1) non-ischemic ATN etio-
of renal diseases. Scatterogram of absolute KIM-1 concentration islogies or (2) various chronic renal diseases contained
shown to discriminate the value of KIM-1 among the different groups
greater amounts of KIM-1 than were found in urines of patients. Number of patients in each group is indicated above the
scatterogram. Values shown are means(SE). Abbreviations are: ATN,from individuals without known renal diseases, the
acute tubular necrosis; Other ARF, acute renal failure with causes otheramount of KIM-1 present was much greater in urines
than ischemia and contrast nephropathy.
from patients with ischemic ATN. KIM-1 Western blot
analysis correlated well with the quantitation of KIM-1
in the urine by ELISA. Both absolute urinary human
KIM-1 concentration and KIM-1 concentration normal- disease. There was no clinical sign of active SLE ne-
ized to urine creatinine concentration were much higher phropathy at the time of urine collection. The urine sedi-
in patients with ischemic ATN than in patients with other ment was benign other than the presence of trace protein.
forms of renal injury (Table 4). When normalized to urinary creatinine concentration,
We determined whether potential confounding vari-
however, the KIM-1/creatinine value was 0.87, a value
ables explained the association between KIM-1 concen-
close to the mean value of the other patients with CRD.tration and ischemic ATN. After adjusting for age, gen-
Our studies do not permit us to identify how early inder, length of time delay between the initial insult and
the course of disease urinary KIM-1 can be detected.sampling of the urine, a one-unit increase in normalized
We do know that levels are detectable within 12 hoursKIM-1 was strongly associated with the diagnosis of
of the insult since one of our patients who had high levelsATN (OR 12.4, 95% CI, 1.2 to 119). The absolute KIM-1
of urinary KIM-1 had a well-documented ischemic epi-concentration showed similar results with this end-point.
sode 12 hours prior to collection of the urine (patient 7,In Figure 3, the urinary KIM-1 values in each of the pa-
Table 3). This finding is consistent with the observedtients are presented. One patient in the CRD group
time course of KIM-1 expression in the urine of a patientwith SLE nephropathy had a high KIM-1 level when
compared to the other eight patients with chronic renal who underwent an elective repair of an abdominal aortic
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urine, including leucine aminopeptidase, alkaline phos-
phatase, 	-glucosidase, and GT, have been used to de-
tect acute and chronic kidney injury induced by drugs
and pollutants [11, 20]. Unfortunately, these markers are
neither universal urinary biomarkers nor do they reflect
a final common pathway of renal expression of injury
[24]. In addition, there are characteristics of each of these
markers that prevent their ready usage in general clinical
settings. The detection of urinary enzyme activity also
is complicated by the frequent loss of activity associated
with the physicochemical characteristics of the urine or
Fig. 4. KIM-1 expression in urine of patient after abdominal aortic the presence of pyuria [25]. In the case of low-molecular-
aneurysm repair. Time course of KIM-1 expression in urine of a patient weight proteinuria, timing of urine collection is impor-
who underwent an elective repair of an abdominal aortic aneurysm.
tant because protein excretion follows a circadian rhythmSequential urine samples were collected every 6 hours from the onset
of operation. Urine sediment was checked at every time point KIM-1 with lowest levels observed during sleep [26]. Tubular
was measured. brush border antigens have been reported to be sensitive
indicators of proximal tubular injury [9, 23]; however,
standard immunoassays for these antigens have not been
developed. In our study, quantitative levels of urinaryaneurysm (Fig. 4). In this patient, KIM-1 was present in
GT, total protein, and alkaline phosphatase did notthe urine within 12 hours after clamping of aorta. It is of
correlate with the extent of functional renal injury norinterest that urinary KIM-1 could be detected before
did these markers distinguish ATN from other causes ofany urinary casts were noted on microscopic examina-
renal insufficiency.tion of the urine.
KIM-1 expression was found in proximal tubule epi-
thelial cells in human kidney biopsy sections from pa-Other urinary biomarkers
tients with ATN. KIM-1, a type 1 transmembrane glyco-Urinary GT, alkaline phosphatase and total protein
protein, is expressed only minimally in a normal adultwere measured for comparison with urinary KIM-1 as
rat kidney and is dramatically up-regulated in the S3markers for ATN (Fig. 5). When either non-normalized
segment of the proximal tubule in post-ischemic rat kid-or normalized to urine creatinine concentration, concen-
neys, under conditions where the S3 segment is highlytrations of these biomarkers, other than KIM-1, did not
susceptible to an ischemic insult [19]. In our study ische-discriminate ATN from other causes of renal failure.
mic ATN appears to be the most common predisposing
factor for elevation of urinary KIM-1 protein in cases of
DISSCUSION ARF. Low levels of KIM-1 expression in random individ-
uals without known renal diseases likely represent back-This study demonstrates that urinary KIM-1 protein
concentration is significantly higher in urine samples from ground of the ELISA assay since no urinary KIM-1 pro-
tein was detected by Western blot in normal volunteers.patients with ischemic ATN compared to urine samples
from patients with other forms of acute and chronic renal Urine samples from patients with diabetic nephropathy
and SLE nephropathy, who had significant proteinuriafailure. We have detected urinary KIM-1 levels with mu-
rine monoclonal antibodies that we developed and have (
3 g/day), but were without evidence for tubule necro-
sis on urine sediments, had no elevation of urinary KIM-1characterized to be highly specific to human KIM-1. The
traditional laboratory approach for detection of renal protein. Thus, high grade proteinuria does not alter the
excretion profile of urinary KIM-1. The normalization ofdisease involves determination of the serum creatinine,
blood urea nitrogen, creatinine clearance, urinary elec- urinary KIM-1 to urine creatinine concentration poses
a limitation since patients with ARF are not in a steadytrolytes, microscopic examination of the urine sediment,
and radiological studies. These indicators are not only state of creatinine balance. The unsteady creatinine vol-
ume output will influence the data considerably. In or-insensitive and nonspecific, but do not allow for early
detection of the disease. In this initial study of the pres- der to minimize this uncertainly, we used both non-nor-
malized urinary KIM-1 and normalized KIM-1 in ourence of KIM-1 in human urine, we report that KIM-1 is
a more specific marker for ischemic tubule injury than study, and the results did not markedly differ. Although
our sample size was small, adjustment for potentiala number of other markers that have been previously
examined. confounders did not diminish the association between
KIM-1 and ATN.Surface membrane components of proximal tubule
epithelia have been previously used as urinary markers Other glycoproteins such as intercellular adhesion
molecule-1 and selectins have been shown to be involvedof injury [9, 11, 20–23]. Brush-border enzyme activities in
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Fig. 5. Comparison of KIM-1 and other uri-
nary proteins as biomarkers for tubule injury
in various renal diseases. Urinary alkaline phos-
phatase, -glutamyltransferase, (GT) and to-
tal protein were measured for comparison
with urine KIM-1 as markers for ATN. Num-
ber of patients in each group is indicated
above the top bars. Urinary biomarker con-
centrations are normalized to urine creatinine
concentration.
in the pathogenesis of ischemic ARF [1]. KIM-1 expres- and may obviate the need for renal biopsy. The presence
of urinary KIM-1 also might be useful as a marker insion has been co-localized with bromodeoxyuridine (a
clinical trials so that therapy can be initiated at an earlymarker for proliferation) and vimentin (a marker for de-
stage in the course of the disease. A sensitive urine test fordifferentiation) staining proximal tubular epithelial cells
proximal tubule injury also will be useful for the eval-in the post-ischemic rat kidney [19]. During the repair
uation of nephrotoxicity of pharmaceutical agents inprocess the proximal tubule epithelium undergoes a
development.complex series of events, including proliferation of sur-
In conclusion, we have demonstrated that a soluble re-viving epithelial cells and formation of a poorly differen-
leased form of human KIM-1 can be detected in the urinetiated regenerative epithelium over the denuded base-
of patients with ischemic ARF and may serve as a novelment membrane [1]. Our study shows that KIM-1 can
biomarker for renal proximal tubule injury. A largerbe expressed in urine within 12 hours after the initial
prospective study is needed to further validate the utilityischemic renal insult, prior to regeneration of the epi-
of this biomarker in the clinical setting.thelium, and persists over time. In animals, it has been
shown that KIM-1 is present coincident with the appear-
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